"We want to do that in a setting of a clinical trial, a large pragmatic clinical trial," Hahn said.
The FDA is also considering a treatment that consists of transfusing blood plasma from a person who has been cured of the coronavirus into a patient who is still infected. The therapy, called convalescent plasma, is still under investigation and could be another three to six months away.
"What's also important is not to provide false hope, but to provide hope," Hahn said. "Let me make one thing clear: FDA's responsibility to the American people is to ensure that products are safe and effective."
Hahn added that vaccines are in early testing phases and will likely be in trials for at least another year. However, he said development on vaccines is "exciting work," and it's happening in "record time."
"This is a continuous process; there is no beginning and end to each of this," Hahn said. "We're pushing this through."
(Article changed on March 24, 2020 at 21:53)
(Article changed on March 25, 2020 at 16:51)
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
